|Day's Range||0.1300 - 0.1400|
|52 Week Range||0.0200 - 6.4900|
|PE Ratio (TTM)||-0.06|
|Earnings Date||Mar 23, 2017 - Mar 24, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
NEW YORK, June 05, 2017-- Delcath Systems, Inc. announced today that its 2017 Annual Meeting of Stockholders, scheduled for June 5, 2017, was convened and adjourned, without any business being conducted. ...
NEW YORK, May 09, 2017-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended ...
The FDA approved the design of Delcath's clinical trial for its Melphalan HDS chemo delivery product.